LXRX Q1 2024 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+4608.3% YoY

Gross Profit

$955,00084.5% margin

Operating Income

-$45M-4011.8% margin

Net Income

-$48M-4282.9% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+61.0%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$417M

Total Liabilities

$128M

Stockholders' Equity

$289M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$24,000	+4608.3%
Gross Profit	$955,000	$24,000	+3879.2%
Operating Income	-$45M	-$31M	-45.6%
Net Income	-$48M	-$32M	-51.6%